DEUTSCHE BANK AG\ - NEUROCRINE BIOSCIENCES INC ownership

NEUROCRINE BIOSCIENCES INC's ticker is and the CUSIP is 64125CAD1. A total of 35 filers reported holding NEUROCRINE BIOSCIENCES INC in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
DEUTSCHE BANK AG\ ownership history of NEUROCRINE BIOSCIENCES INC
ValueSharesWeighting
Q4 2022$2,522,400
-58.2%
1,600,000
-62.8%
0.00%
-75.0%
Q3 2022$6,033,000
-13.5%
4,300,000
-18.8%
0.00%0.0%
Q2 2022$6,976,000
+10.9%
5,295,000
+10.3%
0.00%
+33.3%
Q1 2022$6,288,000
+5.1%
4,800,0000.0%0.00%0.0%
Q4 2021$5,985,000
+18.8%
4,800,000
+26.3%
0.00%
+50.0%
Q3 2021$5,038,000
-0.8%
3,800,0000.0%0.00%0.0%
Q2 2021$5,080,000
+35.0%
3,800,000
+35.7%
0.00%0.0%
Q1 2021$3,764,000
-2.6%
2,800,0000.0%0.00%0.0%
Q4 2020$3,863,000
+86.3%
2,800,000
+85.7%
0.00%
+100.0%
Q3 2020$2,074,000
-17.3%
1,508,0000.0%0.00%
-50.0%
Q2 2020$2,507,000
-44.5%
1,508,000
-57.2%
0.00%
-50.0%
Q1 2020$4,519,000
-54.1%
3,526,000
-45.2%
0.00%
-33.3%
Q4 2019$9,851,000
+34.1%
6,434,000
+19.9%
0.01%
+20.0%
Q3 2019$7,344,000
-45.3%
5,365,000
-47.5%
0.01%
-37.5%
Q2 2019$13,414,000
-20.8%
10,225,000
-18.4%
0.01%
-20.0%
Q1 2019$16,932,000
+36.4%
12,531,000
+20.5%
0.01%
+11.1%
Q4 2018$12,412,000
-82.8%
10,399,000
-75.4%
0.01%
-57.1%
Q3 2018$72,056,000
+55.6%
42,272,000
+31.8%
0.02%
+61.5%
Q2 2018$46,303,00032,084,0000.01%
Other shareholders
NEUROCRINE BIOSCIENCES INC shareholders Q1 2023
NameSharesValueWeighting ↓
III Capital Management 12,500,000$17,262,0003.12%
CSS LLC/IL 24,395,000$33,616,0001.59%
Mint Tower Capital Management B.V. 9,000,000$12,407,0001.46%
Context Partners Fund, L.P. 3,000,000$4,125,0000.90%
Context Capital Management, LLC 3,000,000$4,125,0000.90%
SHENKMAN CAPITAL MANAGEMENT INC 4,258,000$5,971,0000.71%
SSI INVESTMENT MANAGEMENT LLC 5,888,000$8,100,0000.70%
Aequim Alternative Investments LP 3,000,000$4,155,0000.55%
WOLVERINE ASSET MANAGEMENT LLC 32,181,000$44,437,0000.40%
TWO SIGMA SECURITIES, LLC 13,000,000$17,875,0000.36%
View complete list of NEUROCRINE BIOSCIENCES INC shareholders